Novartis AG ADR buy melinda
Start price
25.05.19
/
50%
€79.30
Target price
04.11.21
€90.20
Performance (%)
-8.45%
End price
05.11.21
€72.60
Summary
This prediction ended on 05.11.21 with a price of €72.60. With a performance of -8.45%, the BUY prediction for Novartis AG ADR by melinda closed slightly in the red. Dividends of €5.57 are taken into consideration when calculating the performance. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novartis AG ADR | 1.481% | 1.481% | 37.275% | 45.435% |
| iShares Core DAX® | 0.855% | 1.375% | 2.609% | 52.294% |
| iShares Nasdaq 100 | -0.989% | -3.844% | 25.552% | 78.877% |
| iShares Nikkei 225® | -1.781% | -8.530% | 42.813% | 65.506% |
| iShares S&P 500 | 0.057% | 0.610% | 21.574% | 63.546% |
Comments by melinda for this prediction
In the thread Novartis AG ADR diskutieren
NOVARTIS
Novartis AG
Cycadia (sNDA)
décision de la FDA sur Zykadia en première intention - le traitement des patients atteints de cancer du poumon métastatique non à petites cellules (NSCLC) , dont les tumeurs sont kinase lymphatique anaplasique (ALK) - positif
23/08/2017
La FDA approuve l'utilisation prolongée de Zykadia 26, mai 2017
In the thread Trading Novartis AG ADR
Die von melinda gewählte maximale Laufzeit wurde überschritten